Glucose Tolerance Evaluation in Graves Patients Treated with Methimazole and Radioiodine

This Article

Citations


Article Information:


Group: 2011
Subgroup: Volume 9, Issue 4, Autumn
Date: September 2011
Type: Letter to Editor
Start Page: 377
End Page: 378
DOI: 10.5812/Kowsar.1726913X.2365

Authors:

  • Eijun Nishihara
  • Department of Internal Medicine, Kuma Hospital, Hyogo, Japan
  • Masafumi Koga
  • Department of Internal Medicine, Kinki Central Hospital, Hyogo, Japan

      Correspondence:

      Affiliation: Department of Internal Medicine, Kinki Central Hospital
      City, Province: Hyogo,
      Country: Japan
      Tel: +81-727813712
      Fax: +81-727791567
      E-mail: koga_m@kich.itami.hyogo.jp

Manuscript Body:


  • Please cite this paper as:
    Nishihara E, Koga M. Glucose Tolerance Evaluation in Graves Patients Treated with Methimazole and Radioiodine. Int J Endocrinol Metab. 2011;9(4):377-8. DOI: 10.5812/Kowsar.1726913X.2365
  • Keywords:
    Graves’s Patients; Radioactive Iodine

Copyright © 2012 Kowsar M. P. Co. All rights reserved.


Dear Editor,
The manuscript, “Evaluation of Glucose Tolerance in Methimazole and Radioiodine Treated Graves’ Patients,” by Kiani J et al. (1) compared glucose tolerance in Graves’ disease patients treated with methimazole to those treated with radioiodine. The results indicated that radioiodine therapy had no adverse effects on glucose tolerance or insulin resistance. This study has an impact on whether particular attention should be paid to diabetes mellitus in patients after radioiodine therapy. The conclusion is reasonable, but the design of this study raises several questions concerning glucose tolerance, beyond simply damage to the pancreas caused by radioiodine.
First, not only the present state of thyroid function but also its functional changes throughout each treatment for Graves' disease may affect glucose tolerance. Without knowing the patient’s glucose tolerance before receiving radioiodine, the exact change is difficult to evaluate in each individual. Second, the level of sodium iodide symporter (NIS) expression in the pancreas remains controversial. One report demonstrated strong NIS immunoreactivity in pancreatic islet cells (2). Another report, however, did not find any evidence of NIS immunoreactivity in the pancreas (3). This discrepancy may be caused by the anti-NIS antibodies used in each study. Regardless, in both studies, the NIS expression level in the pancreas was quite low compared to the level in the thyroid gland. Given that TSH stimulates radioiodine uptake in thyroid tissue but not in extrathyroidal tissue because of the absence of TSH receptors, radioiodine accumulation in the pancreas is inhibited in the presence of the thyroid gland. To decrease this interference with radioiodine uptake, more efficient radioiodine accumulation in the pancreas may be one way to administer high doses of radioiodine as pointed out by the authors. Alternatively, thyroid-cancer patients who undergo a total thyroidectomy followed by remnant ablation may be good candidates for evaluation of glucose tolerance in patients after radioiodine therapy (1). In this situation, physiological accumulation of radioiodine can be identified by scintigraphy, and, when present, suggests possible subsequent damage in the tissues. Although it is rare to detect clear radioiodine accumulation in the pancreas of thyroid-cancer patients after radioiodine therapy or development of diabetes mellitus in patients, future studies should still examine this issue because minor side effects are not well understood.

  • Financial Disclosure
    None declared.

References: (3)

  1. Kiani J, Yusefi V, Tohidi M, Mehrabi Y, Azizi F. Evaluation of glucose tolerance in methimazole and Radioiodine treated Graves’ patients. Int J Endocrinol Metab. 2010;8(3):132-7. [Link]
  2. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999;84(11):4178-84. [PubMed][DOI: 10.1210/jc.84.11.4178 ]
  3. Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM. Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol. 1999;141(4):382-6. [PubMed][DOI: 10.1530/eje.0.1410382]